Sweden Chooses to Reject Alzheimer Drug
Swedish health authorities refused a new drug for Alzheimer's. The drug showed potential to slow the disease. Researchers and doctors criticized the decision.
The Swedish National Board of Health and Welfare decided against approving the drug. They said the drug’s cost was too high. Many doctors and researchers disagreed with this decision. They believed the drug could help patients with Alzheimer’s. The researchers had shown the drug could slow the disease’s progress.
Summarized from the sources above. Read the originals for the full story.
Highlights
Alzheimer Drug Rejected by Sweden
Swedish health authorities rejected a new drug that could slow Alzheimer's progression.
Research Shows Drug Benefits
Research showed the drug had potential to slow the disease.
Doctors Criticize the Decision
Leading researchers and doctors criticized the decision.
Flawed Economic Calculation
The decision was due to a flawed health economic calculation.
Patients Not Valued Enough
Critics argue patients are not valued enough in the decision.